Bright Minds Biosciences Inc.
NASDAQ:DRUG · NASDAQ Capital Market
+$0.62 today
Vol 0.24M · Avg 0.27M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$12.2M -336.5% | -$2.8M +62.0% | -$7.4M +50.7% | -$15.0M -73.0% | -$8.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $76.9K +4.8% | $73.4K +1.3% | $72.5K +1100.1% | $6.0K | $0 | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $3.2M +279.0% | $839.8K -27.1% | $1.2M +31.7% | $875.1K -0.6% | $880.6K | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $555.0K +1294.0% | $39.8K +104.2% | -$941.7K -230.0% | $724.1K +136.6% | $306.1K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$362.8K -2639.9% | -$13.2K -111.1% | $118.8K +360.3% | -$45.6K +58.6% | -$110.1K | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $0 | $0 | $0 | $0 | $0 | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $917.8K +1629.9% | $53.1K +105.0% | -$1.1M -237.8% | $769.8K +84.9% | $416.2K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$276.8K -23340.8% | -$1.2K -101.8% | $65.1K +128.6% | -$227.4K -257.1% | $144.8K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$8.7M -369.8% | -$1.9M +73.7% | -$7.0M +48.3% | -$13.6M -85.6% | -$7.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | $0 | $0 | $0 | $0 | $0 | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0 | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$100.2K -11.6% | -$89.7K -4.2% | -$86.1K -1102.3% | -$7.2K | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $86.0M +9455.4% | $900.3K -26.1% | $1.2M -69.8% | $4.0M -85.5% | $27.7M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$360.1K | $0 -100.0% | $1.1M -9.4% | $1.2M +169.2% | -$1.7M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $85.6M +10456.4% | $810.6K -63.0% | $2.2M -57.9% | $5.2M -80.1% | $26.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $312.6K +2567.4% | $11.7K +125.8% | -$45.3K -117.5% | $258.8K +15.7% | $223.8K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $77.2M +7609.4% | -$1.0M +78.9% | -$4.9M +40.0% | -$8.1M -142.9% | $19.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$8.7M -369.8% | -$1.9M +73.7% | -$7.0M +48.3% | -$13.6M -85.6% | -$7.3M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$849.60M
Design Therapeutics, Inc.
NASDAQ:DSGN
$758.85M
Annexon, Inc.
NASDAQ:ANNX
$586.61M
Aura Biosciences, Inc.
NASDAQ:AURA
$399.64M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$307.56M
Altimmune, Inc.
NASDAQ:ALT
$240.01M
I-Mab
IMAB
$235.66M
Galectin Therapeutics Inc.
NASDAQ:GALT
$183.48M
Korro Bio, Inc.
NASDAQ:KRRO
$125.81M
enGene Holdings Inc.
NASDAQ:ENGN
$87.54M
SEC Filings
Recent regulatory filings
No filings found.
Does DRUG generate free cash flow?
Bright Minds Biosciences Inc. (DRUG) generated -$8,691,619.00 of free cash flow in fiscal 2025.
How much operating cash flow does DRUG produce?
Operating cash flow was -$8,691,619.00, before capital expenditures of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.